The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
Open accessAbstract
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis. OBJECTIVES: To determine the 16-week efficacy and safety of two oral tofacitinib doses vs. placebo in patients with moderate-to-severe chronic plaque psoriasis. METHODS: Patients in two similarly designed phase III studies (OPT Pivotal 1, NCT01276639, n = 901; OPT Pivotal 2, NCT01309737, n = 960) were initially randomized 2 : 2 : 1 to tofacitinib 10 or 5 mg or placebo, twice daily. Coprimary efficacy end points (week 16) included the proportion of patients achieving Physician's Global Assessment (PGA) of 'clear' or 'almost clear' (PGA response) and the proportion achieving ≥ 75% reduction in Psoriasis Area and Severity Index (PASI 75). RESULTS: Across OPT Pivotal 1 and OPT Pivotal 2, 745 patients received tofacitinib 5 mg, 741 received tofacitinib 10 mg and 373 received placebo. At week 16, a greater proportion of patients achieved PGA responses with tofacitinib 5 and 10 mg twice daily vs. placebo (OPT Pivotal 1, 41·9% and 59·2% vs. 9·0%; OPT Pivotal 2, 46·0% and 59·1% vs. 10·9%; all P < 0·001). Higher PASI 75 rates were observed with tofacitinib vs. placebo (OPT Pivotal 1, 39·9%, 59·2% and 6·2%, respectively, for tofacitinib 5 and 10 mg twice daily and placebo; OPT Pivotal 2, 46·0%, 59·6% and 11·4%; all P < 0·001 vs. placebo). Adverse event (AE) rates appeared generally similar across groups; rates of serious AEs, infections, malignancies and discontinuations due to AEs were low. Twelve patients reported herpes zoster across the tofacitinib treatment groups in both studies vs. none in the respective placebo groups. The most common AE across groups was nasopharyngitis. CONCLUSIONS: Oral tofacitinib demonstrated significant efficacy vs. placebo during the initial 16 weeks of treatment in patients with moderate-to-severe psoriasis. Safety findings were consistent with prior studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
Self-citationJanus kinases in immune cell signaling
Ghoreschi, K., Laurence, A., & O’Shea, J. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00754.x · Cited by 1,149
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Menter, A., Tyring, S. K., Gordon, K., Kimball, A. B., Leonardi, C. L., Langley, R. G., Strober, B. E., Kaul, M., Gu, Y., Okun, M., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.09.010 · Cited by 889
Self-citationSaurat, J. ‐., Stingl, G., Dubertret, L., Papp, K. A., Langley, R. G. B., Ortonne, J. ‐., Unnebrink, K., Kaul, M., Camez, A., & for the CHAMPION Study Investigators (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08315.x · Cited by 728
Self-citationPathirana, D., Ormerod, A., Saiag, P., Smith, C., Spuls, P., Nast, A., Barker, J., Bos, J., Burmester, G., Chimenti, S., et al. (2009) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2009.03389.x · Cited by 703
Lebwohl, M. G., Bachelez, H., Barker, J., Girolomoni, G., Kavanaugh, A., Langley, R. G., Paul, C. F., Puig, L., Reich, K., & van de Kerkhof, P. C. M. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.12.018 · Cited by 515
Self-citationBritish Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009
Smith, C. H., Anstey, A. V., Barker, J. N. W. N., Burden, A. D., Chalmers, R. J. G., Chandler, D. A., Finlay, A. Y., Griffiths, C. E. M., Jackson, K., McHugh, N. J., et al. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09505.x · Cited by 464
Bachelez, H., van de Kerkhof, P. C. M., Strohal, R., Kubanov, A., Valenzuela, F., Lee, J.-H., Yakusevich, V., Chimenti, S., Papacharalambous, J., Proulx, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62113-9 · Cited by 410
Self-citationLi, D.-Q., Chen, Z., Song, X. J., Luo, L., & Pflugfelder, S. C. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-0299 · Cited by 392
Armstrong, A. W., Robertson, A. D., Wu, J., Schupp, C., & Lebwohl, M. G. (2013) · JAMA Dermatology · doi:10.1001/jamadermatol.2013.5264 · Cited by 386
Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
Winthrop, K. L., Yamanaka, H., Valdez, H., Mortensen, E., Chew, R., Krishnaswami, S., Kawabata, T., & Riese, R. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38745 · Cited by 353
Papp, K. A., Menter, A., Strober, B., Langley, R. G., Buonanno, M., Wolk, R., Gupta, P., Krishnaswami, S., Tan, H., & Harness, J. A. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2012.11168.x · Cited by 338
Self-citationSchmitt, J. M., Rosumeck, S., Thomaschewski, G., Sporbeck, B., Haufe, E., & Nast, A. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12663 · Cited by 157
Bissonnette, R., Iversen, L., Sofen, H. L., Griffiths, C. E. M., Foley, P. A., Romiti, R., Bachinsky, M., Rottinghaus, S. T., Tan, H., Proulx, J., et al. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13551 · Cited by 151
Self-citationWeger, W. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00702.x · Cited by 144
McInnes, I. B., Kim, H., Lee, S., Mandel, D. R., Song, Y.-W., Connell, C. A., Luo, Z., Brosnan, M. J., Zuckerman, A. L., Zwillich, S. H., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202442 · Cited by 127
Jakpot! New small molecules in autoimmune and inflammatory diseases
Ghoreschi, K., & Gadina, M. (2013) · Experimental Dermatology · doi:10.1111/exd.12265 · Cited by 126
Targeting the Jak/STAT pathway for immunosuppression
O’Shea, J. J. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.028290 · Cited by 93
Kimball, A. B., Rothman, K. J., Kricorian, G., Pariser, D. M., Yamauchi, P. S., Menter, A., Teller, C. F., Aras, G. A., Accortt, N. A., Hooper, M. M., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.08.050 · Cited by 73
Signorovitch, J., Betts, K. A., Yan, Y. S., LeReun, C., Sundaram, M., Wu, E. Q., & Mulani, P. M. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13437 · Cited by 69
The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions
Adelzadeh, L., Jourabchi, N., & Wu, J. J. (2013) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12307 · Cited by 63
Cited by
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0701-9 · Cited by 1,206
The role of JAK/STAT signaling pathway and its inhibitors in diseases.
Xin, P., Xu, X., Deng, C., Liu, S., Wang, Y., Zhou, X., Ma, H., Wei, D., & Sun, S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106210 · Cited by 1,010
Alinaghi, F., Calov, M., Kristensen, L. E., Gladman, D. D., Coates, L. C., Jullien, D., Gottlieb, A. B., Gisondi, P., Wu, J. J., Thyssen, J. P., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.06.027 · Cited by 673
Self-citationBanerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0736-y · Cited by 590
Metadata
- Authors
- Papp, K. A., Menter, M. A., Abe, M., Elewski, B., Feldman, S. R., Gottlieb, A. B., Langley, R., Luger, T., Thaci, D., Buonanno, M., Gupta, P., Proulx, J., Lan, S., Wolk, R., & the OPT Pivotal 1 and OPT Pivotal 2 investigators
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-10
- Volume
- 173
- Issue
- 4
- Pages
- 949-961
- ISSN
- 0007-0963 (ISSN-L)
- OpenAlex
- W1892175722
- Cited by
- 327
- References
- 21
- FWCI
- 14.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.